1. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis
- Author
-
Sanja Stanojevic, Joseph L. Mathew, Louise Taylor, Felix Ratjen, and Valerie Waters
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Cystic Fibrosis ,Patient characteristics ,macromolecular substances ,medicine.disease_cause ,Cystic fibrosis ,Pediatrics ,Drug Administration Schedule ,Risk Factors ,Internal medicine ,Administration, Inhalation ,Secondary Prevention ,medicine ,Tobramycin ,Humans ,Pseudomonas Infections ,Pediatrics, Perinatology, and Child Health ,Child ,Intensive care medicine ,Eradication ,Dose-Response Relationship, Drug ,business.industry ,Pseudomonas aeruginosa ,medicine.disease ,Antimicrobial ,Anti-Bacterial Agents ,Respiratory Function Tests ,Clinical trial ,Chronic infection ,Treatment Outcome ,Inhaled tobramycin ,Child, Preschool ,Chronic Disease ,Pediatrics, Perinatology and Child Health ,Female ,Drug Monitoring ,business ,medicine.drug - Abstract
BackgroundInhaled tobramycin therapy has been shown to be efficacious in clinical trials for the eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis (CF). However, the effectiveness of different regimens in eradicating P. aeruginosa and preventing the development of chronic infection in actual clinical settings has yet to be determined.MethodsThis was an observational study of children (
- Full Text
- View/download PDF